Literature DB >> 7882569

Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue.

Y Utsunomiya1, M Ogura, T Kawamura, T Mitarai, N Maruyama, O Sakai.   

Abstract

Although prostaglandins have been shown to inhibit the evolution of the nephritis in NZB/W mice, the mechanisms of this effect are unknown. To characterize such inhibition, we injected the prostacyclin (PGI2) analogue, beraprost, into NZB/W mice, using 0.5 mg, 1.0 mg or 5.0 mg beraprost/kg body weight of test animals three times in 1 week when the mice were 2 months old. Evaluation included measurement of urine albumin excretion, serological parameters and splenic T cell subset, as well as examination of renal histology by light and fluorescence microscopy. Mice given beraprost showed a marked decrease in urine albumin excretion and in glomerular hypercellularity compared with untreated controls. Maximal beneficial effects occurred when the dose was 5.0 mg/kg of beraprost. These effects correlated with a reduction of immune complex deposition in glomeruli. In addition, beraprost reduced serum levels of immunoglobulins and anti-double-stranded DNA antibodies, and decreased the number of helper (L3T4+) T cells in splenocytes. These results indicate that beraprost attenuates the nephritis of NZB/W mice, and that the source of this effect is the reduced production of autoantibodies and deposition of immune complexes in glomeruli.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7882569      PMCID: PMC1534207          DOI: 10.1111/j.1365-2249.1995.tb05572.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

Review 1.  The immunology and pathology of NZB mice.

Authors:  J B Howie; B J Helyer
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

2.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

3.  Prostaglandin E treatment of NZB/NZW mice.

Authors:  R B Zurier; D M Sayadoff; A B Torrey; N F Rothfield
Journal:  Arthritis Rheum       Date:  1977-03

4.  NZB/NZW mice as a model of systemic lupus erythematosus.

Authors:  E L Dubois; R E Horowitz; H B Demopoulos; R Teplitz
Journal:  JAMA       Date:  1966-01-24       Impact factor: 56.272

5.  Regulation of human mesangial cell growth in culture by thromboxane A2 and prostacyclin.

Authors:  P Menè; H E Abboud; M J Dunn
Journal:  Kidney Int       Date:  1990-08       Impact factor: 10.612

6.  The hemodynamic effects of prostaglandins in the rat. Evidence for important species variation in renovascular responses.

Authors:  J G Gerber; A S Nies
Journal:  Circ Res       Date:  1979-03       Impact factor: 17.367

7.  Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. Changes with mitogen dose and preincubation.

Authors:  J S Goodwin; R P Messner; G T Peake
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

8.  Attenuation of anti-Thy1 glomerulonephritis in the rat by anti-inflammatory platelet-inhibiting agents.

Authors:  K Poelstra; E Brouwer; J F Baller; M J Hardonk; W W Bakker
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

9.  Pathogenesis of the glomerulonephritis of NZB/W mice.

Authors:  P H Lambert; F J Dixon
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

10.  The viral envelope glycoprotein of murine leukemia virus and the pathogenesis of immune complex glomerulonephritis of New Zealand mice.

Authors:  T Yoshiki; R C Mellors; M Strand; J T August
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

View more
  3 in total

1.  Therapeutics in renal disease: the road ahead for antiproliferative targets.

Authors:  Peter J Nelson; Stuart J Shankland
Journal:  Nephron Exp Nephrol       Date:  2005-12-07

2.  A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design.

Authors:  Hidetomo Nakamoto; Toshiro Fujita; Hideki Origasa; Masanao Isono; Hajimu Kurumatani; Kiyonobu Okada; Hiroyuki Kanoh; Takashi Kiriyama; Shunsuke Yamada
Journal:  BMC Nephrol       Date:  2014-09-19       Impact factor: 2.388

3.  Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial.

Authors:  Akio Koyama; Toshiro Fujita; Fumitake Gejyo; Hideki Origasa; Masanao Isono; Hajimu Kurumatani; Kiyonobu Okada; Hiroyuki Kanoh; Takashi Kiriyama; Shunsuke Yamada
Journal:  BMC Nephrol       Date:  2015-10-16       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.